The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

    Research output: Contribution to journalArticlepeer-review


    The management of RA, SpA, psoriasis and inflammatory bowel disease has significantly improved over the last decade with the addition of tumour necrosis factor inhibitors (anti-TNFs) to the therapeutic armamentarium. Immunogenicity in response to monoclonal antibody therapies (anti-drug antibodies) may give rise to low serum drug levels, loss of therapeutic response, poor drug survival and/or adverse events such as infusion reactions. To combat these, the use of concomitant MTX may attenuate the frequency of anti-drug antibodies in RA, SpA and Crohn's disease. Although a similar effect to methotrexate has been observed with AZA usage in the management of Crohn's disease, there is insufficient evidence to suggest that other DMARDs impact immunogenicity. In this article we review the evidence to date on the effect of immunomodulatory therapy when co-administered with anti-TNFs. We also discuss whether such a strategy should be employed in SpA and psoriasis, and if optimization of the MTX dose could improve biologic drug survival and thereby benefit disease management. © The Author(s) 2013. Published by Oxford University Press on behalf of the British Society to Rheumatology.
    Original languageEnglish
    Article numberket260
    Pages (from-to)213-222
    Number of pages9
    Issue number2
    Publication statusPublished - Feb 2014


    • Anti-drug antibodies
    • Anti-TNFs
    • Azathioprine
    • Biologics
    • Disease-modifying anti-rheumatic drugs
    • Immunogenicity
    • Methotrexate


    Dive into the research topics of 'The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases'. Together they form a unique fingerprint.

    Cite this